With anti-VEGF agents, systemic circulation may increase the risk of thromboembolic events, myocardial infarction, stroke, and hypertension among other adverse events due to disruptions in the regulation of proinflammatory genes [83,84]. Here, VEGFA is linked to hypertensive disorder.